Our Team
Biao He, PhD
Chief Executive Officer
Dr. He is the inventor of the PIV5 platform and is the Fred C. Davison Distinguished University Chair in Veterinary Medicine at the University of Georgia (UGA; currently on leave of absence). He has over 20 years of experience in vaccine research with over 70 peer-reviewed publications. Prior to being recruited to UGA, Dr. He was a tenured professor at Penn State University in the Department of Veterinary and Biomedical Sciences.
Gary Titus
Chief Financial Officer
Mr. Titus has over 25 years of experience as a finance professional in the biotech industry. He has previously served as CFO for several public and private biotech companies including UroGen Pharma (NASDAQ:URGN) which he took public in 2017, SciClone Pharma, and Kosan Biosciences (NASDAQ:KOSN) through its sale to Bristol-Myers Squibb in 2008.
Hong Jin, PhD
Chief Scientific Officer
Dr. Jin has over 20 years of R&D experience with vaccines and infectious disease therapies at AstraZeneca, MedImmune, and Aviron, including working on their FluMist (the first marketed intranasal vaccine) and RSV programs.
Samuel Wu, MD, PhD
Chief Business Officer
Dr. Wu has over 20 years of experience in private and corporate venture capital, including with MedImmune Ventures and SV Health Investors. He has served as a board director for multiple biotechnology and medical device companies (public and private, including vaccine-focused).
Barbara Solow, PhD
SVP, Program Management and Contracts
Barb brings over 20 years of experience in product development and government contracting, including leading vaccine development and manufacturing programs from pre-clinical through commercial stages. She previously headed external development and contracting at Curia and at Emergent, and has led R&D teams and consulted for various other biopharma companies.
Hank Radziewicz, MD, MSCR
Chief Medical Officer
Dr. Raziewicz is a board-certified infectious disease specialist and clinical trialist who trained at Duke University and Emory University. He has over 20 years of clinical experience and expertise in infectious disease and vaccines.
Helen Zhu, PhD MBA
VP, Controller
Dr. Zhu has over 25 years of experience in accounting and finance in the healthcare industry. She has previously served as CFO and Controller for Cardiovascular Clinical Sciences, a full-service clinical research organization, and obtained a PhD in Biochemistry prior to embarking on her finance career.
Marinka Tellier, PhD
Chief Regulatory Officer
Dr. Tellier has over 25 years of experience as a regulatory professional, including 7 years with NSF International and 15 years for the NIH/NIAID, where she was responsible for developing vaccines and anti-infectives. Her expertise covers all phases of biologics and drug development from preclinical through marketing, for global and start-up as well as government clients.